The importance of angiogenesis markers in the outcome of patients with diffuse large B cell lymphoma: A retrospective study of 97 patients

Journal of Cancer Research and Clinical Oncology

Volumn 134, Issue 3, 2008, Pages 381-387

  Ganjoo, Kristen N ^a,c   Moore, Annette M ^b   Orazi, Attilio ^b   Sen, Joy A ^b   Johnson, Cynthia S ^b   An, Caroline S ^b  

^a STANFORD UNIVERSITY   (United States)

^b INDIANA UNIVERSITY   (United States)

^c NONE   (United States)

Author keywords

Diffuse large B cell lymphoma (DLBCL); International prognostic index (IPI); Vascular endothelial growth factor (VEGF)

Indexed keywords

CD31 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 1; VINCRISTINE;

ADULT; AGED; ANGIOGENESIS; ARTICLE; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR BIOPSY;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 38649131327     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-007-0294-x     Document Type: Article

References (36)

1. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A et al (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403(6769):503-511
2. Bairy O, Zimra Y, Kaganovsky E, Shaklai M, Okon E, Rabizadeh E (2000) Microvessel density in chemosensitive and chemoresistant diffuse large B cell lymphomas. Med Oncol 17(4):314-318
3. Cao Y, Linden P, Farnebo J, Cao Renhai, Eriksson A, Kumar V et al (1998) Vascular endothelial growth factor C induces angiogenesis in vivo. Proc Natl Sci USA 95(24):14389-14394
4. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 346:235-242
5. De Varies C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT (1992) The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255(5047):989-991
6. Dmoszynska A, Podhorecka M, Manko J, Bojarska-Junak A, Rolinski J, Skomra D et al (2005) The influence of thalidomide therapy on cytokine secretion, immunophenotype, BCL-2 expression and microvessel density in patients with resistant or relapsed multiple myeloma. Neoplasm 52:175-181
7. Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocrinol Rev 25(4):581-611
8. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM et al (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002-1006
9. Ganjoo KN, An CS, Robertson MJ, Gordon LI, Sen JA, Weisenbach J et al (2006) Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis. Leuk Lymphoma 47(6):998-1005
10. Gordon LI, Harrington D, Anderson J, Colgan J, Glick J, Neiman R et al (1991) Comparison of a second generation combination chematherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced non-Hodgkin's lymphoma. N Engl J Med 327:1342-1349
11. Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB et al (2006) Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma. J Clin Oncol 24:3121-3127
12. Hazar B, Paydas S, Zorludemir S, Sahin B, Tuncer I (2003) Prognostic significance of Microvessel density and vascular endothelial growth factor (VEGF) expression in non-Hodgkin's lymphoma. Leuk Lymphoma 44:2089-2093
13. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainswirth J, Heim W et al (2004) Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342
14. Jeltsch M, Kaipainen A, Joukov V, Meng X, Lakso M, Rauvala H et al (1997) Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 276:1423-1425
15. Kadowaki I, Ichinohasama R, Harigae H, Ishizawa K, Okitsu Y, Kameoka J et al (2005) Accelerated lymphangiogenesis in malignant lymphoma: possible role of VEGF-A and VEGF-C. Br J Haematol 130(6):869-877
16. Masood R, Cai J, Zheng T, Smith DL, Naidu Y, Gill PS (2001) Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood 98:1904-1913
17. Miller KD, Wang M, Gralow J, Dickler M, Cobleigh MA, Perez EA et al (2005) A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100). San Antonio breast symposium
18. Olofsson B, Korpelainen E, Pepper MS, Mandriota SJ, Aase K, Kumar V et al (1998) Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci USA 95(20):11709-11714
19. Park JE, Chen HH, Winer J, Houck KA, Ferrara N (1994) Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not Flk-1/KDR. J Biol Chem 269(41):25646-25654
20. Pedersen LM, Klausen TW, Davidsen UH, Johnsen HE (2005) Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non-Hodgkin's lymphoma. Ann Hematol 84:510-516
21. Pepper MS, Tille JC, Nisato R, Skobe M (2003) Lymphangiogenesis and tumor metastasis. Cell Tissue Res 314(1):167-177
22. Perez-Atayde AR, Sallan SE, Tedrow U, Connors S, Allred E, Folkman J et al (1997) Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol 150:815-821
23. Pfreundschuh, Trümper L, Österborg A, Pettengell R, Trneny M, Imrie K et al (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7(5):379-391
24. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L et al (1997) Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57:4593-4599
25. Ribas C, Colleoni GW, Silva MR, Carregoza MJ, Bordin Jo (2004) Prognostic significance of vascular endothelial growth factor immunoexpression in the context of adverse standard prognostic factors in multiple myeloma. Eur J Haematol 73:311-317
26. Ribatti D, Vacca A, Marzullo A, Nico B, Ria R, Roncali L et al (2000) Angiogenesis and mast cell density with tryptase activity increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas. Int J Cancer 85(2):171-175
27. Salven P, Orpana A, Teerenhovi L, Joensuu H (2000) Simultaneous elevation in the serum concentrations of angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin's lymphoma: a single institution study of 200 patients. Blood 96:3712-3718
28. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non- small cell lung cancer. N Engl J Med 355(24):2542-2550
29. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P et al (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565
30. Smolej L, Andrys C, Maisnar V, Pour L, Maly J (2005) Plasma concentrations of vascular endothelial growth factor and basic fibroblast growth factor in lymphoproliferative disorders. Acta Medica 48:57-58
31. Stopeck AT, Bellamy W, Unger J, Rimsza L, Iannone M, Fisher RI et al (2005) Phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin's lymphoma (NHL): Southwest Oncology Group Study S0108. Proceedings of ASCO (abstract 6592)
32. Stopeck A, Iannone M, Rimsza L, Miller T, Fisher R, Bellamy W (2004) Expression of VEGF, VEGF receptors, and other angiogenic markers in relapsed aggressive non-Hodgkin's lymphoma: correlative Studies from the SWOG S0108 Trial. Blood 104(11) (abstract 2288)
33. The international non-Hodgkin's lymphoma prognostic factors project (1993) A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987-994
34. Wang ES, Teruya-Feldstein J, Wu Y, Zu Z, Hicklin DJ et al (2004) Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo. Blood 104:2893-2902
35. Weidner N (1995) Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res treat 36(2):169-180
36. Wrobel T, Mazur G, Dziegiel P, Jelen M, Szuba A, Kuliczkowski K et al (2006) Density of intranodal lymphatics and VEGF-C expression in B-cell lymphoma and reactive lymph nodes. Folia histochem cytobiol 44(1):43-47